Figure 6
Kaplan-Meier survival curves of the U87ΔEGFR and GL261 mouse glioma models and of the GL261 mouse syngeneic models treated with Ad-SGE-REIC or Ad-CAG-REIC.
(A) At 7 days after U87ΔEGFR cell implantation to BALB/c mice, mice were treated with Ad-SGE-REIC, Ad-CAG-REIC, or Ad-LacZ (3.6 × 107 pfu) by direct intratumoral injection. The survival time of mice treated with Ad-SGE-REIC was significantly longer than that of those treated with Ad-LacZ or Ad-CAG-REIC (median survival = 22, 18, and 19 days, respectively; P = 0.0038 and P = 0.0107) (n = 10 each group). (B) At 7 days after GL261 cell implantation to BALB/c mice, mice were treated with Ad-SGE-REIC, Ad-CAG-REIC, or Ad-LacZ (3.6 × 107 pfu) by direct intratumoral injection. The survival time of mice treated with Ad-SGE-REIC was significantly longer than that of those treated with Ad-LacZ (median survival = 41 and 33 days; P = 0.0257) (n = 10 each group). (C) At 7 days after GL261 cell implantation to C57BL/6N mice, mice were treated with Ad-SGE-REIC, Ad-CAG-REIC, or Ad-LacZ (3.6 × 107 pfu) by direct intratumoral injection. The survival time of mice treated with Ad-CAG-REIC was significantly longer than that of those treated with Ad-LacZ (median survival = 47 and 36 days, respectively; P = 0.024). The survival time of mice treated with Ad-SGE-REIC was significantly longer than that of those treated with Ad-LacZ (median survival = 103 and 36 days, respectively; P = 0.004) (n = 10 each group).
